ストックスクリーナーアプリを入手
8.94
1.97%
-0.18
プレマーケット:
8.81
-0.13
-1.45%
Arcus Biosciences Inc (RCUS) 最新ニュース
Renaissance Technologies LLC Lowers Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result - GuruFocus
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry - simplywall.st
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Long Term Trading Analysis for (RCUS) - news.stocktradersdaily.com
Wells Fargo & Company MN Has $575,000 Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Taking the lead: Arcus Biosciences Inc (RCUS) - Sete News
Arcus Biosciences Inc (RCUS) Stock: Navigating a Year of Volatility - investchronicle.com
Can you now get a good deal on Arcus Biosciences Inc’s shares? - uspostnews.com
Arcus Biosciences Inc [RCUS] Investment Guide: What You Need to Know - knoxdaily.com
Arcus Biosciences Inc (NYSE: RCUS) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Invesco Ltd. - Defense World
Barclays Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $14.00 - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
RCUSArcus Bioscience Latest Stock News & Market Updates - Stock Titan
Are Arcus Biosciences Inc (RCUS) shares a good deal now? - uspostnews.com
Russell Investments Group Ltd. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences to Present First Combination Data for HIF-2a I - GuruFocus
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting | RCUS Stock News - GuruFocus
Groundbreaking Kidney Cancer Treatment Data: Arcus Reveals First Casdatifan-Cabozantinib Results at ASCO 2025 - Stock Titan
Arcus Biosciences Inc (RCUS) Is A Buy According To Analysts - Marketing Sentinel
Forecasting The Future: 5 Analyst Projections For Arcus Biosciences - Benzinga
Arcus Biosciences (RCUS) Price Target Slashed by Barclays to $14 - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update | RCUS Stock News - GuruFocus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update - Business Wire
Arcus Biosciences to Host Conference Call to Discuss First-Quart - GuruFocus
Geode Capital Management LLC Decreases Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
ARCUS BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain restricted stock units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain Options of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Alliancebernstein L.P. - Defense World
Norges Bank Buys Shares of 34,044 Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Vanguard Group Inc. Sells 79,539 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Corebridge Financial Inc. Sells 2,258 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
American Century Companies Inc. Increases Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Announces New Employment Inducement Grants - Bluefield Daily Telegraph
Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies - Investing.com Australia
Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies By Investing.com - Investing.com South Africa
Arcus Biosciences' SWOT analysis: biotech stock's potential in cancer therapies - Investing.com
Raymond James Financial Inc. Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
RCUS stock touches 52-week low at $7.5 amid market challenges - Investing.com Australia
RCUS stock touches 52-week low at $7.5 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
(RCUS) Trading Signals - news.stocktradersdaily.com
Institutional owners may consider drastic measures as Arcus Biosciences, Inc.'s (NYSE:RCUS) recent US$134m drop adds to long-term losses - simplywall.st
Arcus Biosciences patents new c-Kit inhibitors - BioWorld MedTech
Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo
RCUS stock touches 52-week low at $8.81 amid market challenges - Investing.com
Cancer Therapy Pioneer Arcus Biosciences Accelerates Growth with Key Team Expansion - Stock Titan
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Amundi - Defense World
RCUS stock touches 52-week low at $8.97 amid market challenges - Investing.com Australia
RCUS stock touches 52-week low at $8.97 amid market challenges By Investing.com - Investing.com South Africa
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):